Generic Drug Competition Hurts Biovail

Shares of Biovail Corp. (BVF) dropped $2.13 to $24.50 over concerns that the Food and Drug Administration will make it easier for generic drug companies to bring generic versions of Biovail's Wellbutrin to market.